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a b s t r a c t
Nimodipine has been shown to have an inhibitory action on seizures and brain damage in rodents. How-
ever, the pharmaceutical applicability of this drug is limited by its low solubility in gastrointestinal
ﬂuids and high ﬁrst-pass effect in the liver, which leads to low bioavailability. These difﬁculties can
be overcome through the use of liposomes. The aim of the present study is to evaluate the toxicity and
anticonvulsant activity of liposomes containingnimodipine (NMD-Lipo) onpilocarpine-induced seizures.
NMD-Lipowas prepared using the lipid-ﬁlm hydrationmethod. Central nervous system toxicity of NMD-
Lipo was assessed by Hippocratic screening. Systemic toxicity was evaluated by analyses of biochemical
and hematological parameters and by observing possible signs of toxicity. The possible anticonvulsant
activity was tested by the pilocarpine model. The administration of the NMD-Lipo at doses of 0.1, 1, and
10mg/kg caused no toxicity in animals. Furthermore, NMD-Lipo prevented the installation of 100% of the
pilocarpine-induced seizures andprevented the death of 100% of themice treatedwith pilocarpine. These
data shown that NMD-Lipo has an anticonvulsant activity signiﬁcantly superior to free NMD, suggesting
that the liposomes promoted a drug controlled release by improving its bioavailability and consequently
increasing its pharmacological activity.
© 2014 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Epilepsy is a chronic disease of the central nervous system char-
acterized by recurrent seizures caused by excessive discharges of
cerebral neurons. This condition is a health concern, as it is consid-
ered one of the most serious neurological disorders [1]. Clinically,
patients with the disease experience a deterioration of one or more
http://dx.doi.org/10.1016/j.neulet.2014.11.025
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cognitive functions, with or without motor behavior and/or psy-
chomotor decrease [2].
Seizures can be completely controlled with medical therapy in
two-thirds of patients; however, one-third remains refractory to
the medications [3]. Furthermore, the current antiepileptic drugs
used in the treatment of epilepsy have a wide range of adverse
reactions, toxicity, and teratogenic effects. Based on these ﬁndings,
new therapeutic agents, which allow more efﬁcient seizure control
in resistant patients and with fewer side effects, are greatly needed
[4].
Research has shown that the intrinsic epileptiform activ-
ity is associated with calcium (Ca2+) inﬂux through NMDA
receptor-operated Ca2+ channels and through voltage-operated
Ca2+ channels. Therefore, the inhibition of the intracellular Ca2+
increase represents an important target in the development of
antiepileptic and neuroprotective drugs [5]. From this perspective,
calcium channel blockers may be considered as a possible thera-
peutic agent for the disease.
Nimodipine (NMD) is a dihydropyridine L-type Ca2+ channel
antagonist that crosses the blood–brain-barrier more easily than
other calcium-channel-blockers and binds with high afﬁnity and
speciﬁcity to the calcium-channel receptors in the brain [6]. NMD
has been shown to have an inhibitory action on seizures and
brain damage in rodents [16–23]. However, the pharmaceutical
applicability of nimodipine is limited by its low solubility in gas-
trointestinalﬂuids andhighﬁrst-pass effect in the liver,which leads
to low bioavailability after oral administration [7,8].
These difﬁculties can be overcome through theuse of liposomes.
These nanometer-scale pharmaceutical carriers are self-assembled
colloidal vesicles consistingof oneormore concentric phospholipid
bilayers organized around an aqueous inner compartment, and are
used to encapsulate drugs, biomolecules or diagnostic agents [9].
The aim of the present study is two fold: the evaluation of the
nimodipine encapsulated into liposomes (NMD-Lipo) toxicity and
the study of anticonvulsant activity of NMD-Lipo on pilocarpine-
induced seizures.
2. Materials and methods
2.1. Reagents
Cholesterol (CHOL), trehalose, nimodipine, and pilocarpine
hydrochloride were purchased from Sigma–Aldrich (St. Louis,
USA). Soybean phosphatidylcholine (PC) (98% Epikuron 200)
was obtained from Lipoid GMBH (Ludwigshafen, Germany). Sol-
vents and other chemicals were supplied by Merck (Darmstadt,
Germany).
2.2. Animals
Adult male Swiss mice (25–30g; 2 months old) were obtained
from Central Animal House of the Federal University of Piaui, Piaui,
Brazil. They were maintained in a temperature controlled room
(25±1 ◦C), with a 12h light/dark cycle (lights on 07:00–19:00h),
and food and water provided ad libitum (Nutrilabor, Campinas,
Brazil). The experimental protocols and procedures were approved
by the Ethics Committee on Animal Experimentation of the Federal
University of Piauí (CEEA/UFPI N◦ 014/11). All experiments were
performed according to the guide for the care and use of laboratory
of the US, Department of Health and Human Services, Washington,
DC (1985).
2.3. Preparation and characterization of liposomes containing
nimodipine
Liposomes containing nimodipine (NMD-Lipo) were prepared
and characterized as previously described [10]. The content of
nimodipine in liposomes was determined using UV spectroscopy
at 237nm and the encapsulation efﬁciency of nimodipine into
liposomes was determined after the submission of samples to
ultraﬁltration/ultracentrifugation using Ultrafree® units (Milli-
pore, USA), for the separation of the drug encapsulated and non
encapsulated into liposomes [10]. The content of nimodipine in the
supernatantwas then determined and the drug encapsulation ratio
was calculated as:
%EE = [NMD]content − [NMD]free
NMDcontent
× 100.
2.4. Systemic and central nervous system toxicity of NMD-Lipo
Mice were divided into four groups, with 16 animals in each
group. The ﬁrst group was treated with 0.9% saline. The second,
third, and fourth groups were treated with NMD-Lipo at doses of
0.1, 1, and 10mg/kg. NMD is a widely used drug and its security
is well-known, so the toxicity tests have not been conducted with
free NMD, only with NMD-Lipo.
Central nervous system toxicity of NMD-Lipo was assessed by
Hippocratic screening. Systemic toxicity was evaluated by analy-
sis of biochemical and hematological parameters and by observing
possible signs of toxicity.
Half of the animals in each group (n=8) were observed for 24h
andsubsequentlywere intended to implement theblood tests.Dur-
ing this period we proceeded to the observation of the mice at the
time of 30min, 1, 2, 4, 8, 12, and 24h for the purpose of quantifying
the effect of NMD-Lipo on the following parameters: (a) state of
awareness and readiness; (b) motor coordination; (c) muscle tone;
(d) reﬂection (atrial and cornea); (e) central nervous system activ-
ity; (f) autonomic nervous system activity. At the end of 24h, the
animals were anesthetized with pentobarbital 40mg/kg and blood
was immediately collected from the retro-orbital plexus for the
assessment of biochemical and hematologic parameters [11].
The other half (n=8) was under observation for a period of 30
days for viewing and the recording of possible signs of toxicity of
the formulation. During these 30 days, the consumption of water
and feed was recorded daily, body weight of mice was measured
every two days and the animals were evaluated for clinical signs of
toxicity.
2.5. Anticonvulsant activity of NMD-Lipo
Mice were divided into twenty-two groups, with each group
containing 12 animals. The negative control group was treated
with 0.9% saline. The P400 group was treated with pilocarpine
hydrochloride at a dose of 400mg/kg to induce seizures. The third
and fourth groups were treated with diazepam at a dose of 5mg/kg
and an association of diazepam with pilocarpine hydrochloride
in a dose of 400mg/kg. The ﬁfth, sixth, and seventh groups were
treated with empty liposomes at doses of 0.1, 1, and 10mg/kg. The
eighth, ninth, and tenth groupswere treatedwith empty liposomes
at doses of 0.1, 1, and 10mg/kg and after 30min they received
pilocarpine hydrochloride at the dose of 400mg/kg. The eleventh,
twelfth, and thirteenth groups were treated with free nimodip-
ine at doses of 0.1, 1, and 10mg/kg. The fourteenth, ﬁfteenth, and
sixteenth groups were treated with free nimodipine at doses of
0.1, 1, and 10mg/kg and after 30min they received pilocarpine
hydrochloride at the dose of 400mg/kg. The seventeenth, eigh-
teenth, and nineteenth groups were treated with NMD-Lipo at the
doses of 0.1, 1, and 10mg/kg. Finally, the animals of the twenti-
eth, twenty-ﬁrst, and twenty-second groups received NMD-Lipo at
the doses of 0.1, 1, and 10mg/kg and after 30min they received
pilocarpine hydrochloride at the dose of 400mg/kg.
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After the treatments, the animals were recorded in
30 cm×30 cm chambers with: appearance of peripheral cholin-
ergic signs (miosis, piloerection, chromodacryorrhea, diarrhea,
and urination), stereotyped movements (continuous snifﬁng,
paw licking, and rearing), tremors, seizures, status epilepticus,
and mortality rate, during 24h. We decided to observe possible
changes in the behavior of mice for 24h after pilocarpine admin-
istration because previous works showed that convulsions and
deaths occurred within 1 and 24h, respectively, post pilocarpine
injection [12].
2.6. Statistical analyses
The results were presented as a percentage according to the
number of animals used in the experiments. Peripheral cholinergic
signs, stereotypic movements, tremor, seizures, status epilepticus,
and mortality rate were presented as percentages and compared
with a nonparametric test (Chi-Square test). In all situations sta-
tistical signiﬁcance was reached at p less-than-or-equals, slant
0.05. The statistical analyses were performed with the software




NMD-Lipo presented a drug content of 0.98±0.58mg/ml and
encapsulation efﬁciency of 99±0.22%.
3.2. Systemic and central nervous system toxicity of NMD-Lipo
In the Hippocratic screening, NMD-Lipo did not cause any
behavioral alterations in mice at the doses tested. Therefore, no
alteration was observed in biochemical and hematologic parame-
ters as any variation inweight ofmice treatedwith the formulation.
None of the animals treated with NMD-Lipo died.
3.3. Behavioral alterations after pretreatment with NMD-Lipo
The results of the behavioral alterations of animals after
pretreatment with NMD-Lipo after 24h of phase acute of
pilocarpine-induced seizures are summarized in Table 1. None of
the mice that received injections of isotonic saline (negative con-
trol), diazepam, empty liposomes, free nimodipine, and NMD-Lipo
unassociatedwithpilocarpine showedperipheral cholinergic signs,
Table 1
Effect of pretreatment with NMD-Lipo, free nimodipine, liposomes, and diazepam on pilocarpine-induced seizures and lethality in adult mice.
Groups (n=12) Peripheral cholinergic signs Stereotypic movements Tremor Seizures Status epilepticus Mortality rate
% % % % % %
Negative control 00 00 00 00 00
P400 100a 100a 100a 100a 75a 75a
DZP 5 plus P400 100a 100a 100a 50a,b 50a,b 50a,b
DZP 5 00 00 00 00 00 00
Lipo 0.1 00 00 00 00 00 00
Lipo 1 00 00 00 00 00 00
Lipo 10 00 00 00 00 00 00
NMD-Lipo 0.1 plus P400 100a 65a,b,c,d,e 100a 00b,c,d,e 00b,c,d,e 00b,c,d,e
Lipo 0.1 plus P400 100a,c 100a,c 100a,c 100a,c 75a,c 75a,c
Lipo 1 plus P400 100a,d 100a,d 100a,d 100a,d 75a,d 75a,d
Lipo 10 plus P400 100a,e 100a,e 100a,e 100a,e 75a,e 75a,e
Free NMD 0.1 00 00 00 00 00 00
Free NMD 1 00 00 00 00 00 00
Free NMD 10 00 00 00 00 00 00
Free NMD 0.1 plus P400 100a,f 100a,f 100a,f 100a,f 50a,b,f 75a,f
Free NMD 1 plus P400 100a,g 100a,g 100a,g 100a,g 50a,b,g 75a,g
Free NMD 10 plus P400 100a,h 75a,b,h,*,** 100a,h 100a,h 75a,h,*,** 75a,h
NMD-Lipo 0.1 00 00 00 00 00 00
NMD-Lipo 1 00 00 00 00 00 00
NMD-Lipo 10 00 00 00 00 00 00
NMD-Lipo 0.1 plus P400 100a,i 65a,b,i,& 100a,i 00b,& 00b,& 00b,&
NMD-Lipo 1 plus P400 100a,j 40a,b,j,#,& 60a,b,j,#,##,& 00b,& 00b,& 00b,&
NMD-Lipo 10 plus P400 100a,l 30a,b,l,#,##,& 20a,b,l,#,##,& 00b,& 00b,& 00b,&
Mice (25–30g; 2 months old) were treated acutely with vehicle (saline 0.25ml, negative control), pilocarpine (400mg/k.g, i.p, P400), diazepam (5mg/kg, i.p., DZP 5, positive
control), empty liposomes (Lipo), free nimodipine (Free NMD), and liposomal formulation containing nimodipine (NMD-Lipo) at doses 0.1, 1 e 10mg/kg (i.p.). Others groups
of mice were pretreated acutely with Lipo, free NMD and NMD-Lipo at doses 0.1, 1 e 10mg/kg (i.p.) or DZP and 30min after treatment with pilocarpine 400mg/kg, i.p. Results
for peripheral cholinergic signs, stereotypic movements, tremor, seizures, status epilepticus, and death are expressed as percentages of the number of animals from each
group.
a p<0.05, when compared with negative control.
b p<0.05, when compared with P400 group.
c p<0.05, when compared with Lipo 0.1.
d p<0.05, when compared with Lipo 1.
e p<0.05, when compared with Lipo 10.
f p<0.05, when compared with Free NMD 0.1.
g p<0.05, when compared with Free NMD 1.
h p<0.05, when compared with Free NMD 10.
i p<0.05, when compared with NMD-Lipo 0.1.
j p<0.05, when compared with NMD-Lipo 1.
l p<0.05, when compared with NMD-Lipo 10.
* p<0.05, when compared with Free NMD 0.1 plus P400.
** p<0.05, when compared with Free NMD 1 plus P400.
# p<0.05, when compared with NMD-Lipo 0.1 plus P400.
## p<0.05, when compared with NMD-Lipo 1 plus P400.
& p<0.05, when compared with DZP 5 plus P400 (Chi-Square test).
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stereotypic movements, tremor, and seizures. None of the animals
in these groups died.
All animals treated with P400 alone presented peripheral
cholinergic signs and stereotyped movements followed by motor
limbic seizures. The convulsive process persisted and built up to a
status epilepticus in 75% of these mice, leading to death of 75%
of the animals. Diazepam at the dose of 5mg/kg did not sig-
niﬁcantly reduce the occurrence of peripheral cholinergic signs,
stereotypicmovements, and tremors. The benzodiazepinewas able
to reduce by 50% the occurrence of seizures and by 33.33% the
mortality rate in mice. Empty liposomes at doses of 0.1, 1, and
10mg/kg did not reduce the occurrence of peripheral choliner-
gic signs, stereotypic movements, and tremor. Liposomes without
nimodipine were unable to prevent the installation of the seizure
and decrease the mortality rate in rodent. Free NMD at the dose of
0.1mg/kg did not reduce the occurrence of peripheral cholinergic
signs, stereotypic movements, and tremors. The unencapsulated
drug at the dose of 0.1mg/kg was unable to prevent the installa-
tion of the seizure and reduce themortality rate inmice. Aswith the
mice pretreated with free NMD at the dose of 0.1mg/kg, free NMD
at the dose of 1mg/kg did not signiﬁcantly reduce the occurrence of
peripheral cholinergic signs, stereotypic movements, and tremors.
Moreover, free NMD at the dose of 1mg/kg was unable to prevent
the installation of the seizure and reduce the mortality rate in the
mice. Free NMD at doses of 10mg/kg did not signiﬁcantly reduce
the occurrence of peripheral cholinergic signs or tremors and was
not able to prevent the installation of seizures. Free NMD at the
dose of 10mg/kg was able to reduce by 25% of stereotypic move-
ments but was unable to prevent the installation of the seizure and
reduce the mortality rate in the mice.
NMD-Lipo at doses of 0.1, 1, and 10mg/kg did not reduce the
occurrence of peripheral cholinergic signs, but decreased stereo-
typic movements and tremors in the mice. NMD encapsulated into
liposomes at all doses tested was able to prevent the occurrence of
100% of the seizures. None of the mice pretreated with NMD-Lipo
and subsequently given with pilocarpine died.
4. Discussion
Animal models of seizure have been widely used in research
to provide a better understanding of the pathophysiology of the
disease, since they reproduce several components of humanepilep-
sies. Pilocarpine-induced seizures is a model commonly used to
investigate the anticonvulsant effect of antiepileptic drugs [13].
The administration of high doses of pilocarpine induces seizure
activity, followed by a latent seizure-free period preceding the
development of spontaneous recurrent focal seizures. The induc-
tion of status epilepticus by pilocarpine in rodents leads to
neuropathological changes, such as hippocampal sclerosis and
mossy ﬁber sprouting, resembling human temporal lobe epilepsy
[14]. In the present study, we investigated the effects of a liposo-
mal formulation containing nimodipine, a Ca2+ channel blocker, on
susceptibility to seizures induced by pilocarpine in adult mice.
Antiepileptic drugs have different targets such as receptors,
synaptic machinery, and ion channels [15]. Previous studies have
demonstrated that increased levels of intracellular Ca2+ in hip-
pocampal neurons play an important role in the underlying mech-
anisms of neuronal hyperexcitability that leads to pilocarpine-
induced seizures [16]. Research conducted with Ca2+ channel
blocker NMD at the doses of 1 to 300mg/kg have suggested that
the drug presents anticonvulsant activity on seizures induced by
picrotoxin [17], kainic acid [18], aminophylline [19], pentylenete-
trazole [20], phenytoin [21], pilocarpine, and lithium-pilocarpine
[22–24] in mice and rats. However, in all aforementioned studies,
the drug was unable to prevent 100% of seizures.
One of the possible reasons explaining the lack of ability of
nimodipine to prevent the installation of seizures in some rodents
is that the drug has low bioavailability (4–13%) due to its high ﬁrst-
pass effect in the liver [25]. This hypothesis is strengthened by
our data, since NMD-Lipo showed anticonvulsant activity signiﬁ-
cantly superior to free NMD, suggesting that the encapsulation of
the nimodipine into liposomes increases its bioavailability, as well
as the anticonvulsant activity of the drug on the animals.
Nimodipine has a high lipophilicity and it can be easily incor-
porated into the lipid bilayer of the liposomes [26]. NMD-Lipo
presented drug encapsulation efﬁciency of 99±0.22%, showing
that the formulation does not present a signiﬁcant amount of
unloaded NMD. The treatment with NMD-Lipo at the doses of
0.1–10mg/kg was demonstratedto be safe for mice, since these
treatments do not cause changes in the hematological and bio-
chemical parameters of the animals are found. Furthermore,
NMD-Lipo did not cause any change in the weight of the animals,
a signiﬁcant factor as the reduction in body weight is a simple and
sensitive index of toxicity after exposure to a toxic substance [27].
The administration of the liposomal formulation at the doses of
0.1, 1, and 10mg/kgwas able to reduce stereotypicmovements and
tremors.Moreover, NMD-Lipo prevented the installation of 100% of
the pilocarpine-induced seizures and prevented the death of 100%
of the mice treated with pilocarpine, showing even better results
than the rodents treated with diazepam. The results of the anti-
convulsant activity suggest that NMD has a dose-dependent effect.
As expected, empty liposomes showed no anticonvulsant activity,
suggesting that the liposomes potentiate the anticonvulsant effect
of nimodipine.
Animal studies indicate that seizures at an early stage of devel-
opment can drastically affect the construction of networks of the
hippocampus, which can cause the onset of other disorders such as
schizophrenia [28]. The decrease in the occurrence of stereotypic
movements and tremors and the ability to prevented seizures, and
death in rodents constitutes a major advance in drug development
against epilepsy. Thus, a formulation that prevents the emergence
of seizures appears promising in the epilepsy therapy.
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